Cite

HARVARD Citation

    Xuhong, J. et al. (2020). Neoadjuvant Pyrotinib plus Trastuzumab and Chemotherapy for Stage I–III HER2‐Positive Breast Cancer: A Phase II Clinical Trial. Oncologist. pp. e1909-e1920. [Online]. 
  
Back to record